Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics. Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming. Klotho has signed a letter of intent (LOI) in this regard. The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions. Under the LOI's t ...